TOPRA advisory council adds FDA’s Lumpkin
FDA Deputy Commissioner for International & Special Programs Murray Lumpkin is appointed to The Organization for Professionals in Regulatory Affairs' International Advisory Council. The council was created in 2004 to act as a "confidential advisory committee providing strategic direction" to the regulatory affairs organization. The thirteen member council is comprised of many members from industry, as well as a representative from the Danish Medicines Agency and the Irish Medicines Board...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.